NASDAQ OMX

Karolinska Development publishes prospectus relating to set off issue

17.3.2017 08:02 | NASDAQ OMX

Dela

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

STOCKHOLM - March 17, 2017. Karolinska Development AB's (publ) ("Karolinska Development" or the "Company") prospectus relating to a new issue of B-shares to the Company's convertible holders, with payment by set-off (the "Set-off Issue") was approved by and registered with the Swedish Financial Supervisory Authority on March 16, 2017.

The prospectus relating to Karolinska Development's Set-off Issue is now available at the Company's website (www.karolinskadevelopment.com) and the SEB Emissioner's website (www.sebgroup.se/prospectuses).

Karolinska Development has retained Advokatfirman Lindahl as legal adviser in connection with the Set-off Issue. SEB Emissioner acts as issuing agent in connection with the Set-off Issue.
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com 

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The Company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com.

Important information
The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in Karolinska Development. Any invitation to the persons concerned to subscribe for shares in Karolinska Development will only be made through the prospectus referred to in this press release.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, New Zealand, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to those required under Swedish laws and regulations. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No shares have been or will be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"), or securities legislation in any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, in or into the United States, except pursuant to an available exemption from the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.

This press release may contain forward-looking statements which reflect Karolinska Development's current view on future events and financial and operational development. The words "intend", "estimate", "expect", "may", "plan", "anticipate" or similar expressions regarding indications or predictions of future developments or trends and which are not statements based on historical facts constitute forward-looking information. Although Karolinska Development believes that these statements are based on reasonable assumptions and expectations, Karolinska Development cannot give any assurances that such statements will materialize. Forward-looking statements are in its nature involved with both known and unknown risks and uncertainties, since it is depending on future events and circumstances. Forward-looking statements do not constitute any representations and warranties, and the outcome could differ materially from the information set out in the forward-looking statements.

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obligated to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of Jim Van heusden, on March 17, 2017 at 08:00 (CET).




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Forterra Announces Second Quarter 2017 Earnings Schedule27.7.2017 22:30Pressmeddelande

IRVING, Texas, July 27, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra") (Nasdaq:FRTA) plans to release second quarter 2017 financial results before the market open on Thursday, August 10, 2017.  A conference call to review financial results will also be held on Thursday, August 10, 2017 at 8:30 a.m. Eastern time (7:30 a.m. Central).  Hosting the call will be Jeff Bradley, Chief Executive Officer, and Matt Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q2 2017 Forterra, Inc. Earnings Call Date: Thursday, August 10, 2017 Time: 8:30 a.m. Eastern Time (7:30 a.m. Central) Webcast: http://edge.media-server.com/m/p/uxphuyzt Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Parti

TGS Q2 2017 webcast and teleconference27.7.2017 18:14Pressmeddelande

ASKER, Norway, July 27, 2017 (GLOBE NEWSWIRE) -- TGS will release its Q2 2017 results at approximately 07:00 CEST on 3 August 2017. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at the Hotel Continental, Stortingsgata 24/26 in Oslo, Norway. The presentation is open to the public and can be followed live on the internet at www.tgs.com. The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. CEO Kristian Johansen and CFO Sven Børre Larsen will host a conference call on 3 August 2017 at 15:00 CEST (09:00 EDT). Attendees may want to call 5-10 minutes before to ensure registration and access. Norwegian attendees are invited to call + 800 51084 or + 47 2100 2610 International attendees are invited to call 0800 358 6377 or + 44 (0)330 336 9105 US attendees are invited to call +1 866-

Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36Pressmeddelande

VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850  VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at www.vistajet.cn HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching

Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30Pressmeddelande

Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.  The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270.  A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com.  The archived webcast will be available on the Company's website beginning approximately two hours after

Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22Pressmeddelande

Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus

TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00Pressmeddelande

-   Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia -   TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum